We recently demonstrated that blockade of the mineralocorticoid receptor (MR) effectively ameliorated GC-induced skin atrophy in healthy human skin explants and epidermal MR knockout mice. However, whether MR blockade improves the therapeutic index of glucocorticoids (GCs) in skin pathology was not investigated. We assessed the effects of GCs, MR antagonists (MRA) or both, in SDS-treated human skin explants. All treatments restored SDS-augmented epidermal thickness but only GC plus MRA restored the expression of COL1A1. However, MRA alone or in combination with GCs may exert a dual role in regulating inflammatory cytokines. Thus, although combined treatment may be beneficial to improve irritative skin, extensive in vivo testing is required to establish whether the anti-inflammatory effects of GCs are maintained in the presence of MRA.
| BACKGROUND
Skin inflammatory diseases are commonly treated with topical glucocorticoids (GCs) because of their antiproliferative and antiinflammatory effects. [1] However, their use is limited due to adverse side effects such as skin atrophy characterised by tissue thinning caused by inhibition of keratinocyte and fibroblast proliferation and a reduction in the collagen synthesis. [1, 2] Also, local steroidogenic activity is key to homoeostatic prevention or attenuation of skin pathology. [3, 4] Glucocorticoids bind and activate two closely related receptors, the GC receptor (GR) and the mineralocorticoid receptor (MR). Our recent work using genetic and pharmacological approaches in mouse skin and healthy skin of volunteers and human skin explants has shown that MR inactivation ameliorates GC-induced skin atrophy. [5, 6] In both settings, MR blockade improved the epidermal thinning partially reversing the keratinocyte proliferation inhibition induced by topical GC treatments. [5, 6] However, GCs similarly reduced Col1a1 mRNA levels in MR epidermal knockout and control mice indicating that inactivation of dermal MR is also necessary for the effective reversion of skin atrophy.
[5]
| QUESTIONS ADDRESSED
We have analysed whether GC treatment combined with pharmacological MR inhibition achieves a better therapeutic index in an irritative model in human skin explants.
| EXPERIMENTAL DESIGN

| Human skin explants culture and treatments
Human skin biopsies were obtained from three different subjects.
After adipose tissue excision, 6-mm full-thickness punches were obtained of each subject, placed in organotypic culture floating with the dermis embedded into the medium and used for one independent experiment. Human skin explants were cultured in medium DMEM 1× with GlutaMAX, 10% charcoal-stripped fetal bovine serum and 1%
penicillin/streptomycin and incubated at 37ºC, 5% CO 2 . [6] SDS (15 μg/ml; Merck, Darmstadt, Germany) was added to the medium during 3 days then washed, and explants were treated with 100 nmol L 
| RESULTS
Using human skin explants, we have mimicked an irritative pathology by adding SDS to the medium. [7] After 3 days, SDS-induced tissue damage was revealed in haematoxylin and eosin stained sections by cell ballooning ( Figure 1A , arrows), increased dermal cellularity ( Figure 1A) and augmented epidermal thickness ( Figure 1A ,B). These features were similar to those observed in human skin topically treated with SDS. [8, 9] However, SDS did not affect collagen deposition or mRNA expression levels relative to vehicle-treated samples ( Figure S1A ,B).
We assessed the therapeutic effectiveness of the GC clobetasol, the Figure S1A ,B). This is consistent with previous data reporting that the induced expression of COL1A1 in human dermal fibroblast was effectively blocked by treatment with the MRA spironolactone. [10] Importantly, the combined treatment using clobetasol and canrenoate was also effective in decreasing the SDS-induced epidermal thickening ( Figure 1A,B) . In addition, this treatment was the only that improved the collagen deposition and significantly induced COL1A1 mRNA levels as compared to each compound used separately ( Figure S1A ,B).
We also evaluated the expression of keratin (K)6, a marker of keratinocyte hyperproliferation that is found in healthy palmar and plantar skin as well as diseased skin, in explants treated with SDS alone or in combination with the indicated compounds. After SDS treatment, all epidermal layers stained positive for K6; this expression was significantly reduced by clobetasol, which was confined to the upper epidermal layers, but unaffected by canrenoate (Figure 2A ). The combined treatment reduced the effectiveness of clobetasol alone as it produced an intermediate effect with K6 being expressed in several suprabasal layers ( Figure 2A ). These results suggest that complete K6 inhibition by GCs requires functional MR.
Next, we assessed whether the anti-inflammatory effects of GCs were preserved after blocking MR. We analysed the expression of the pro-inflammatory cytokines IL-6 and IL1A and a key enzyme in prostaglandin biosynthesis, COX-2, which are upregulated after SDS treatment in human keratinocytes [11] or skin. [8, 12] Clobetasol significantly Figure 2B ). However, canrenoate triggered both anti-inflammatory effects, with decreased expression of IL-6 and COX-2, and also pro-inflammatory, with upregulation of IL1A mRNA levels ( Figure 2B ). The use of clobetasol plus canrenoate resulted in attenuated or lack of repression of IL-6 and IL1A, respectively, while it had no effect in the inhibition of COX-2 relative to clobetasol alone ( Figure 2B ). Also, consistent with its reported induction by GCs, [13] clobetasol upregulated the mRNA levels of the anti-inflammatory cytokine IL-10 in SDStreated skin explants ( Figure 2B ). While canrenoate did not affect IL-10 mRNA levels, clobetasol plus canrenoate resulted in a trend towards increased transcript levels without reaching statistical significance, suggesting that MR blockade affects GC-dependent induction of IL-10.
These results show that MR may exert a dual role in skin inflammation. 
| CONCLUSIONS
